Format

Send to

Choose Destination
Future Oncol. 2019 Jul;15(20):2337-2348. doi: 10.2217/fon-2019-0021. Epub 2019 Jun 11.

Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.

Author information

1
Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

Abstract

Von Hippel-Lindau (VHL), a tumor suppressor gene, is frequently inactivated in renal cell carcinoma (RCC). It drives tumorigenesis by activating downstream hypoxia responsive genes and proangiogenic factors like VEGFR, and is responsible for the activity of tyrosine kinase inhibitors in RCC. Resistance to VEGFR therapy eventually occurs, in part due to activation of alternative signaling pathways like AXL and MET. Cabozantinib is a potent inhibitor of VEGF, AXL and MET receptors providing rationale for its use in RCC. Cabozantinib has been approved for use in the first- and second-line setting in patients with advanced RCC. This manuscript reviews the preclinical data, pharmacology, clinical efficacy and safety of the use of cabozantinib in RCC.

KEYWORDS:

AXL; CABOSUN; MET; METEOR; VEGFR; cabozantinib; clinical trial; renal cancer

PMID:
31184937
DOI:
10.2217/fon-2019-0021

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center